Free Newsletter
BMS is lead player in patent-approval race
Free newsletter via e-mail
Tools
Which biopharma company was granted the most pharma patents last year? Pharmalot asked IFI Patent Intelligence the question and came up with Bristol-Myers Squibb, with 82. Wyeth, Pfizer, Hoffman LaRoche, Merck, AstraZeneca and Eli Lilly followed in due order of innovation. These are all class 514 patents approvals, as distinct from filings. As Pharmalot points out, there is always a hefty backlog of patent filings. Interestingly, Sanofi-Aventis, which has been hammered by the analysts for its thin pipeline, came out near the bottom of the list, behind the University of California. Tech companies put the biopharma industry to shame though. IBM alone filed 3,148 patents last year.
- read the report from Pharmalot
Related Articles:
Patent 'cliff' looms for Big Pharma. Report
Standards on biotech patents get tougher. Report
Sanofi underscores pipeline advances, setbacks. Report
More stories about Wyeth Sanofi-Aventis pipeline Pfizer Merck Eli Lilly Bristol-Myers Squibb AstraZeneca
Comments
By Anonymous | Posted 4:56pm | January 15, 2008
It’s hard to tell from the graph, but GlaxoSmithKline appears to have about the same number of patent awards as BMS. The patents for SmithKline Beecham must be added to the awards for Glaxo Group LTD if you are fairly comparing the biopharmas of 2007.
Click here to get the FierceBiotech email newsletter for FREE!
Comments (1) | Post a comment